Title : Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.

Pub. Date : 2017 Oct 12

PMID : 29022906






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Increasing AR by HIF-2alpha inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Sorafenib androgen receptor Homo sapiens
2 Here, we demonstrated that the sorafenib-induced or hypoxia-induced hypoxia inducible factor (HIF)-2alpha could bind to an hypoxia responsive element within 500 bp region of androgen receptor (AR) promoter and thus transcriptionally suppress AR. Sorafenib androgen receptor Homo sapiens
3 Here, we demonstrated that the sorafenib-induced or hypoxia-induced hypoxia inducible factor (HIF)-2alpha could bind to an hypoxia responsive element within 500 bp region of androgen receptor (AR) promoter and thus transcriptionally suppress AR. Sorafenib androgen receptor Homo sapiens
4 Here, we demonstrated that the sorafenib-induced or hypoxia-induced hypoxia inducible factor (HIF)-2alpha could bind to an hypoxia responsive element within 500 bp region of androgen receptor (AR) promoter and thus transcriptionally suppress AR. Sorafenib androgen receptor Homo sapiens
5 Importantly, In vitro and In vivo studies suggested a specific and potent HIF-2alpha inhibitor, PT-2385, could significantly enhance sorafenib efficacy by suppressing HIF-2alpha, increasing AR and suppressing downstream pSTAT3/pAKT/pERK pathways. Sorafenib androgen receptor Homo sapiens